整合素α5（ITGA5）是細(xì)胞表面粘附分子家族的重要成員，常與β1亞基結(jié)合形成α5β1異源二聚體受體。ITGA5因能特異性識別纖維連接蛋白中的RGD序列，被稱作纖維連接蛋白受體，在胚胎發(fā)育、創(chuàng)傷修復(fù)等生理過程中調(diào)控細(xì)胞粘附與遷移。α5β1通過激活細(xì)胞內(nèi)FAK/Src信號網(wǎng)絡(luò)，促進腫瘤細(xì)胞侵襲轉(zhuǎn)移能力，其異常表達與乳腺癌、肝癌、結(jié)直腸癌等惡性腫瘤的進展密切相關(guān)。在特發(fā)性肺纖維化、動脈粥樣硬化等疾病中，ITGA5也參與異常細(xì)胞外基質(zhì)沉積過程。目前針對α5β1的靶向藥物已有十余種進入臨床研究，如單抗藥物Volociximab在卵巢癌治療中顯示出抑制血管新生的潛力，小分子抑制劑JSM6427則應(yīng)用于眼底黃斑病變的干預(yù)。由于整合素家族存在功能代償效應(yīng)，部分藥物在臨床試驗中出現(xiàn)療效波動，如何精準(zhǔn)調(diào)控其活性仍是研發(fā)難點。

熱銷產(chǎn)品

ITGA5 Recombinant Monoclonal Antibody (CSB-RA011868MA1HU)

驗證數(shù)據(jù)

IHC image of CSB-RA011868MA1HU diluted at 1:50 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-human polymer IgG labeled by HRP and visualized using 0.05% DAB.